IRIS UniCatt

Salutari, Vanda
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.725
NA - Nord America 1.692
EU - Europa 1.433
SA - Sud America 353
AF - Africa 48
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.257
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.651
SG - Singapore 681
CN - Cina 621
DE - Germania 394
BR - Brasile 290
IT - Italia 251
SE - Svezia 209
FR - Francia 106
VN - Vietnam 98
IN - India 92
IE - Irlanda 89
UA - Ucraina 72
PL - Polonia 64
GB - Regno Unito 62
ID - Indonesia 60
RU - Federazione Russa 53
FI - Finlandia 43
AR - Argentina 29
BD - Bangladesh 25
KR - Corea 23
TR - Turchia 23
HK - Hong Kong 22
CA - Canada 18
NL - Olanda 18
ZA - Sudafrica 17
JP - Giappone 16
AT - Austria 15
MX - Messico 15
IQ - Iraq 13
BE - Belgio 12
PK - Pakistan 10
CH - Svizzera 7
CO - Colombia 7
EC - Ecuador 7
CI - Costa d'Avorio 6
CZ - Repubblica Ceca 6
PY - Paraguay 6
CL - Cile 5
LT - Lituania 5
MA - Marocco 5
SA - Arabia Saudita 5
VE - Venezuela 5
AL - Albania 4
IR - Iran 4
KE - Kenya 4
AU - Australia 3
EG - Egitto 3
ES - Italia 3
IL - Israele 3
KZ - Kazakistan 3
OM - Oman 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
AW - Aruba 2
BG - Bulgaria 2
CR - Costa Rica 2
DZ - Algeria 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
HU - Ungheria 2
JO - Giordania 2
KG - Kirghizistan 2
LB - Libano 2
LV - Lettonia 2
MK - Macedonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PS - Palestinian Territory 2
RO - Romania 2
SN - Senegal 2
TJ - Tagikistan 2
UY - Uruguay 2
UZ - Uzbekistan 2
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BZ - Belize 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GR - Grecia 1
IM - Isola di Man 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MT - Malta 1
NG - Nigeria 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.257
Salva come PNG Salva come JPEG
Città #
Singapore 290
Chandler 249
Ashburn 190
Hangzhou 185
Beijing 131
Dublin 89
Hefei 58
New York 58
Hyderabad 56
Los Angeles 55
Warsaw 55
San Mateo 54
Jakarta 53
Wilmington 48
Ann Arbor 46
Rome 44
Jacksonville 43
Munich 38
Dallas 36
Ho Chi Minh City 36
Redmond 33
Nanjing 31
Boston 30
Milan 29
Moscow 29
Hanoi 26
Houston 26
Bremen 25
Dearborn 24
Frankfurt am Main 24
Cattolica 23
São Paulo 23
Hong Kong 21
Princeton 21
Nürnberg 20
Fairfield 19
Kent 19
Helsinki 18
Seoul 18
The Dalles 18
Redwood City 16
Seattle 16
Johannesburg 14
Naples 14
Marseille 13
Nanchang 13
Woodbridge 13
Buffalo 12
Chicago 12
Izmir 12
Lawrence 12
Santa Clara 12
Shenyang 12
Brooklyn 10
Brussels 10
Tokyo 10
Dhaka 9
Düsseldorf 9
Vienna 9
Washington 9
Atlanta 8
Boardman 8
Cambridge 8
Denver 8
Jiaxing 8
Phoenix 8
Rio de Janeiro 8
Guangzhou 7
Kunming 7
London 7
Mountain View 7
Stockholm 7
University Park 7
Abidjan 6
Amsterdam 6
Bologna 6
Brasília 6
Chennai 6
Detroit 6
Falkenstein 6
Manchester 6
Portsmouth 6
Roubaix 6
Turku 6
Zhengzhou 6
Albano Laziale 5
Bexley 5
Campinas 5
Fortaleza 5
Leawood 5
Andover 4
Ankara 4
Belo Horizonte 4
Bogotá 4
Cosenza 4
Curitiba 4
Goiânia 4
Guayaquil 4
Hebei 4
Karachi 4
Totale 2.763
Salva come PNG Salva come JPEG
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 503
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 337
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence 291
Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results 209
Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery: a diagnostic challenge still unresolved. Correlation between CT findings and CA 125 levels. 173
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. 169
A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations 164
The 'lead vessel': a vascular ultrasound feature of metastasis in the ovaries. 130
Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1). 129
Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study 127
"Occult" ovarian Leydig cell tumor: when laboratory tells more than imaging 125
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall 118
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 118
Optimizing treatment in recurrent epithelial ovarian cancer 115
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 99
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 97
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 96
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall 95
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 92
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients 92
Recent progress in the use of pharmacotherapy for endometrial cancer 91
Immunotherapy-related imaging findings in patients with gynecological malignancies: What radiologists need to know 91
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 90
New medical approaches in advanced ovarian cancer 90
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study 87
Advanced and recurrent endometrial cancer: State of the art and future perspectives 84
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 83
PARP Inhibitors Resistance: Mechanisms and Perspectives 83
Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study 83
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study 83
Controversy in treatment of advanced ovarian cancer 82
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 81
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients 80
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence 79
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 79
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinumbased chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer 74
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 73
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 72
Newly diagnosed ovarian cancer: Which first-line treatment? 72
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: A phase II, open label multicenter study (NUVOLA trial) 71
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 70
Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience" 70
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 70
Combining targeted therapies in ovarian cancer 69
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial) 68
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 68
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: A multicentric Italian experience 66
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 59
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 57
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) 53
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere 51
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: A retrospective single-center experience 49
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 48
Management of early-stage ovarian cancer: Open questions and debated issues 10
Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3/RAD) 9
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study 6
Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial 5
Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer 2
Totale 5.737
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021245 0 0 0 0 0 32 40 30 22 45 59 17
2021/2022286 39 16 2 15 17 6 3 60 5 13 54 56
2022/2023722 67 98 46 104 58 93 27 50 94 20 41 24
2023/2024511 20 131 29 35 18 82 48 15 4 20 53 56
2024/20251.086 28 17 82 39 71 38 40 46 155 135 235 200
2025/20261.478 343 100 224 349 430 32 0 0 0 0 0 0
Totale 5.737